<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226678</url>
  </required_header>
  <id_info>
    <org_study_id>APL2-CP-AIHA-208</org_study_id>
    <nct_id>NCT03226678</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD</brief_title>
  <official_title>An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics
      of APL-2 in subjects with warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease
      (CAD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of AEs</measure>
    <time_frame>12 months from baseline</time_frame>
    <description>The primary safety endpoints of the study are the incidence and severity of treatment emergent adverse events (TEAEs) following administration of multiple doses of subcutaneous (SC) APL-2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in hemoglobin</measure>
    <time_frame>6 months from baseline</time_frame>
    <description>Efficacy endpoint assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>12 months from baseline</time_frame>
    <description>APL-2 serum concentrations and pharmacokinetic (PK) parameter (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>12 months from baseline</time_frame>
    <description>APL-2 serum concentrations and pharmacokinetic (PK) parameter (AUC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Warm Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)</condition>
  <arm_group>
    <arm_group_label>Cohort 1 wAIHA (n=6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 CAD (n=6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-2</intervention_name>
    <description>Complement Inhibitor</description>
    <arm_group_label>Cohort 1 wAIHA (n=6)</arm_group_label>
    <arm_group_label>Cohort 2 CAD (n=6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years of age.

          2. Weight &lt; 125 Kg.

          3. Subjects must have a primary diagnosis of wAIHA or CAD defined by the presence of
             hemolytic anemia and positive DAT for wAIHA (IgG) or CAD (C3).

          4. Hemoglobin &lt;11 g/dL.

          5. Clinical symptoms of hemolysis with abnormal values by any of the hemolytic markers:

               1. Increased absolute reticulocyte count (above ULN)

               2. Reduced haptoglobin (below LLN)

               3. Increased lactase dehydrogenase (LDH) (above ULN)

               4. Increased indirect bilirubin (above ULN)

          6. Women of child-bearing potential (WOCBP) (defined as any female who has experienced
             menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is
             defined as 12 consecutive months with no menses without an alternative medical cause)
             must have a negative pregnancy test at screening and must agree to use protocol
             defined methods of contraception for the duration of the study and 60 days after their
             last dose of study drug.

          7. Males must agree to use protocol defined methods of contraception and agree to refrain
             from donating sperm for the duration of the study and 60 days after their last dose of
             study drug.

          8. Able to provide documentary evidence of Neisseria meningitides types A, C, W, Y and B
             (administered as two separate vaccinations), Pneumococcal conjugate vaccine or
             Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23, respectively) and Haemophilus
             influenzae Type B (Hib) vaccination within 2 years prior to Day -14, OR willing to
             receive vaccinations against Neisseria meningitides at least two weeks prior to dosing
             on Day 1 with a booster after Day 56 (for both vaccinations) and Pneumococcal and Hib
             vaccines prior to dosing on Day 1.

          9. Willing and able to give informed consent.

         10. Specific for wAIHA: Relapsed from, did not respond or relapsed, or did not tolerate,
             at least one prior wAIHA treatment regimen (such as prednisone, rituximab).

        Exclusion Criteria:

          1. Prior treatment with rituximab within 90 days.

          2. Deficiency of iron, folic acid and vitamin B12 prior to treatment phase

          3. Abnormal liver function as indicated by a direct bilirubin above normal level, and/or
             an AST or ALT level &gt; 2x upper limit of normal. Please note elevated indirect
             bilirubin due to hemolysis is not an exclusion criteria.

          4. Active aggressive lymphoma requiring therapy or an active non-lymphatic malignant
             disease other than basal cell carcinoma or CIS of the cervix.

          5. Presence or suspicion of active bacterial or viral infection, in the opinion of the
             Investigator, at screening or severe recurrent bacterial infections.

          6. Participation in any other investigational drug trial or exposure to other
             investigational agent, device, or procedure within 30 days prior to screening period.

          7. Pregnant, breast-feeding, or intending to conceive during the course of the study,
             including the Post-Treatment Phase.

          8. Inability to cooperate or any condition that, in the opinion of the investigator,
             could increase the subject's risk by participating in the study or confound the
             outcome of the study.

          9. Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty,
             stroke, cardiac surgery, or hospitalization for congestive heart failure within 3
             months or &gt; Class 2 Angina Pectoris or NYHA Heart Failure Class &gt;2

         10. QTcF &gt; 470 ms

         11. PR &gt; 280 ms

         12. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart
             Block unless the patient has an implanted pacemaker or implantable cardiac
             defibrillator (ICD) with backup pacing capabilities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federico Grossi</last_name>
    <phone>617-977-5701</phone>
    <email>clinicaltrials@apellis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Apellis Clinical Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>70603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Clinical Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Clinical Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Apellis Clinical Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

